Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.

Sci Rep. 2018 Apr 3;8(1):5584. doi: 10.1038/s41598-018-22938-x.

2.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

3.

NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.

Fiaschetti G, Schroeder C, Castelletti D, Arcaro A, Westermann F, Baumgartner M, Shalaby T, Grotzer MA.

Acta Neuropathol Commun. 2014 Apr 7;2:39. doi: 10.1186/2051-5960-2-39.

4.

The endocytic adaptor Eps15 controls marginal zone B cell numbers.

Pozzi B, Amodio S, Lucano C, Sciullo A, Ronzoni S, Castelletti D, Adler T, Treise I, Betsholtz IH, Rathkolb B, Busch DH, Wolf E, Fuchs H, Gailus-Durner V, de Angelis MH, Betsholtz C, Casola S, Di Fiore PP, Offenhäuser N.

PLoS One. 2012;7(11):e50818. doi: 10.1371/journal.pone.0050818. Epub 2012 Nov 30.

5.

Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.

Fiaschetti G, Castelletti D, Zoller S, Schramm A, Schroeder C, Nagaishi M, Stearns D, Mittelbronn M, Eggert A, Westermann F, Ohgaki H, Shalaby T, Pruschy M, Arcaro A, Grotzer MA.

Oncogene. 2011 Jun 23;30(25):2823-35. doi: 10.1038/onc.2011.10. Epub 2011 Feb 14.

PMID:
21317922
6.

Quassinoids: From traditional drugs to new cancer therapeutics.

Fiaschetti G, Grotzer MA, Shalaby T, Castelletti D, Arcaro A.

Curr Med Chem. 2011;18(3):316-28. Review.

PMID:
21143123
7.

The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors.

Castelletti D, Fiaschetti G, Di Dato V, Ziegler U, Kumps C, De Preter K, Zollo M, Speleman F, Shalaby T, De Martino D, Berg T, Eggert A, Arcaro A, Grotzer MA.

Mol Cancer Ther. 2010 Dec;9(12):3145-57. doi: 10.1158/1535-7163.MCT-10-0539. Epub 2010 Oct 1.

8.

Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD.

Shalaby T, von Bueren AO, Hürlimann ML, Fiaschetti G, Castelletti D, Masayuki T, Nagasawa K, Arcaro A, Jelesarov I, Shin-ya K, Grotzer M.

Mol Cancer Ther. 2010 Jan;9(1):167-79. doi: 10.1158/1535-7163.MCT-09-0586. Epub 2010 Jan 6.

9.

Targeting Myc in pediatric malignancies of the central and peripheral nervous system.

Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A.

Curr Cancer Drug Targets. 2009 Mar;9(2):176-88. Review.

PMID:
19275758
10.

Different glycoforms of prostate-specific membrane antigen are intracellularly transported through their association with distinct detergent-resistant membranes.

Castelletti D, Alfalah M, Heine M, Hein Z, Schmitte R, Fracasso G, Colombatti M, Naim HY.

Biochem J. 2008 Jan 1;409(1):149-57.

PMID:
17935484
11.

Increased ethanol resistance and consumption in Eps8 knockout mice correlates with altered actin dynamics.

Offenhäuser N, Castelletti D, Mapelli L, Soppo BE, Regondi MC, Rossi P, D'Angelo E, Frassoni C, Amadeo A, Tocchetti A, Pozzi B, Disanza A, Guarnieri D, Betsholtz C, Scita G, Heberlein U, Di Fiore PP.

Cell. 2006 Oct 6;127(1):213-26.

12.

Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiency.

Keiser M, Alfalah M, Pröpsting MJ, Castelletti D, Naim HY.

J Biol Chem. 2006 May 19;281(20):14393-9. Epub 2006 Mar 16.

13.

Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing.

Castelletti D, Fracasso G, Alfalah M, Cingarlini S, Colombatti M, Naim HY.

J Biol Chem. 2006 Feb 10;281(6):3505-12. Epub 2005 Oct 12.

14.

Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response.

Castelletti D, Colombatti M.

Int Immunol. 2005 Apr;17(4):365-72. Epub 2005 Feb 21.

PMID:
15724064
15.

Immunotoxins and other conjugates: preparation and general characteristics.

Fracasso G, Bellisola G, Castelletti D, Tridente G, Colombatti M.

Mini Rev Med Chem. 2004 Jun;4(5):545-62. Review.

PMID:
15180510
16.

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, Colombatti M.

Clin Exp Immunol. 2004 May;136(2):365-72.

17.

Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.

Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M.

Prostate. 2002 Sep 15;53(1):9-23.

PMID:
12210476
18.

Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

Tommasi M, Castelletti D, Pasti M, Fracasso G, Lorenzetti I, Sartoris S, Pera C, Ferrara GB, Tridente G, Colombatti M.

Clin Exp Immunol. 2001 Sep;125(3):391-400.

Supplemental Content

Loading ...
Support Center